SMTL ID : 8vtd.1

Co-structure of the Fab of the anti-TIGIT Vibostolimab antibody with its antigen

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.23 Å

Oligo State

hetero-1-1-1-mer

Ligands

2 x GOL: GLYCEROL(Non-functional Binders)

GOL.1: 6 residues within 4Å: Chain A: T.164, E.165, Q.166, D.167 Chain B: V.169, H.170 6 PLIP interactions: 4 interactions with chain B, 2 interactions with chain A Hydrogen bonds: B:V.169, B:H.170, A:D.167 Water bridges: B:T.171, B:T.171, A:S.168 GOL.2: 11 residues within 4Å: Chain A: Q.160, S.162, S.176, S.177, T.178 Chain B: F.172, P.173, V.175, S.183, L.184, S.185 6 PLIP interactions: 3 interactions with chain A, 3 interactions with chain B Hydrogen bonds: A:S.162, A:S.176, A:T.178, B:F.172, B:S.183, B:S.185

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Fischmann, T.O. et al., Pharmacological and structural characterization of vibostolimab, a novel anti-human TIGIT blocking antibody for cancer immunotherapy. To Be Published

Release Date

2025-07-02

Peptides

Vibostolimab Fab Light chain: A
Vibostolimab Fab Heavy chain: B
T-cell immunoreceptor with Ig and ITIM domains: C

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

C
C

Vibostolimab Fab Light chain

Vibostolimab Fab Heavy chain

T-cell immunoreceptor with Ig and ITIM domains

Related Entries With Identical Sequence